Factors significantly predictive of outcome with bortezomib in multivariate analysis
Factor . | P . |
|---|---|
| Response rate | |
| Age ≥ 65 years | .03 |
| Bone marrow plasma-cell infiltration >50% | .03 |
| Time to response, longer | |
| Age ≥ 65 years | .009 |
| Bone marrow plasma-cell infiltration | .021 |
| Duration of response, shorter | |
| Hypoalbuminemia | .003 |
| Low Karnofsky performance score | .01 |
| Time to progression, shorter | |
| Increased C-reactive protein | .011 |
| Abnormal cytogenetics but not chromosome 13 deletion | .02 |
| Overall survival, shorter | |
| Bone marrow plasma-cell infiltration >50% | .028 |
| Hypoalbuminemia | <.001 |
| Thrombocytopenia | .024 |
| Low KPS | .034 |
Factor . | P . |
|---|---|
| Response rate | |
| Age ≥ 65 years | .03 |
| Bone marrow plasma-cell infiltration >50% | .03 |
| Time to response, longer | |
| Age ≥ 65 years | .009 |
| Bone marrow plasma-cell infiltration | .021 |
| Duration of response, shorter | |
| Hypoalbuminemia | .003 |
| Low Karnofsky performance score | .01 |
| Time to progression, shorter | |
| Increased C-reactive protein | .011 |
| Abnormal cytogenetics but not chromosome 13 deletion | .02 |
| Overall survival, shorter | |
| Bone marrow plasma-cell infiltration >50% | .028 |
| Hypoalbuminemia | <.001 |
| Thrombocytopenia | .024 |
| Low KPS | .034 |